Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia

K. Cermáková, P. Tesina, J. Demeulemeester, S. El Ashkar, H. Méreau, J. Schwaller, P. Rezáčová, V. Veverka, J. De Rijck,

. 2014 ; 74 (18) : 5139-51.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15014117

Mixed lineage leukemia (MLL) fusion-driven acute leukemias represent a genetically distinct subset of leukemias with poor prognosis. MLL forms a ternary complex with the lens epithelium-derived growth factor (LEDGF/p75) and MENIN. LEDGF/p75, a chromatin reader recognizing H3K36me3 marks, contributes to the association of the MLL multiprotein complex to chromatin. Formation of this complex is critical for the development of MLL leukemia. Available X-ray data represent only a partial structure of the LEDGF/p75-MLL-MENIN complex. Using nuclear magnetic resonance spectroscopy, we identified an additional LEDGF/p75-MLL interface, which overlaps with the binding site of known LEDGF/p75 interactors-HIV-1 integrase, PogZ, and JPO2. Binding of these proteins or MLL to LEDGF/p75 is mutually exclusive. The resolved structure, as well as mutational analysis, shows that the interaction is primarily sustained via two aromatic residues of MLL (F148 and F151). Colony-forming assays in MLL-AF9(+) leukemic cells expressing MLL interaction-defective LEDGF/p75 mutants revealed that this interaction is essential for transformation. Finally, we show that the clonogenic growth of primary murine MLL-AF9-expressing leukemic blasts is selectively impaired upon overexpression of a LEDGF/p75-binding cyclic peptide CP65, originally developed to inhibit the LEDGF/p75-HIV-1 integrase interaction. The newly defined protein-protein interface therefore represents a new target for the development of therapeutics against LEDGF/p75-dependent MLL fusion-driven leukemic disorders. Cancer Res; 74(18); 5139-51. ©2014 AACR.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014117
003      
CZ-PrNML
005      
20150424103956.0
007      
ta
008      
150420s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/0008-5472.CAN-13-3602 $2 doi
035    __
$a (PubMed)25082813
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cermáková, Kateřina $u KU Leuven, Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
245    10
$a Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia / $c K. Cermáková, P. Tesina, J. Demeulemeester, S. El Ashkar, H. Méreau, J. Schwaller, P. Rezáčová, V. Veverka, J. De Rijck,
520    9_
$a Mixed lineage leukemia (MLL) fusion-driven acute leukemias represent a genetically distinct subset of leukemias with poor prognosis. MLL forms a ternary complex with the lens epithelium-derived growth factor (LEDGF/p75) and MENIN. LEDGF/p75, a chromatin reader recognizing H3K36me3 marks, contributes to the association of the MLL multiprotein complex to chromatin. Formation of this complex is critical for the development of MLL leukemia. Available X-ray data represent only a partial structure of the LEDGF/p75-MLL-MENIN complex. Using nuclear magnetic resonance spectroscopy, we identified an additional LEDGF/p75-MLL interface, which overlaps with the binding site of known LEDGF/p75 interactors-HIV-1 integrase, PogZ, and JPO2. Binding of these proteins or MLL to LEDGF/p75 is mutually exclusive. The resolved structure, as well as mutational analysis, shows that the interaction is primarily sustained via two aromatic residues of MLL (F148 and F151). Colony-forming assays in MLL-AF9(+) leukemic cells expressing MLL interaction-defective LEDGF/p75 mutants revealed that this interaction is essential for transformation. Finally, we show that the clonogenic growth of primary murine MLL-AF9-expressing leukemic blasts is selectively impaired upon overexpression of a LEDGF/p75-binding cyclic peptide CP65, originally developed to inhibit the LEDGF/p75-HIV-1 integrase interaction. The newly defined protein-protein interface therefore represents a new target for the development of therapeutics against LEDGF/p75-dependent MLL fusion-driven leukemic disorders. Cancer Res; 74(18); 5139-51. ©2014 AACR.
650    _2
$a zvířata $7 D000818
650    _2
$a vazebná místa $7 D001665
650    _2
$a HIV-integrasa $x chemie $x metabolismus $7 D019427
650    _2
$a histonlysin-N-methyltransferasa $x chemie $x genetika $x metabolismus $7 D011495
650    _2
$a lidé $7 D006801
650    _2
$a mezibuněčné signální peptidy a proteiny $x chemie $x genetika $x metabolismus $7 D036341
650    _2
$a akutní myeloidní leukemie $x genetika $x metabolismus $7 D015470
650    _2
$a MFC-7 buňky $7 D061986
650    _2
$a magnetická rezonanční spektroskopie $7 D009682
650    _2
$a myši $7 D051379
650    _2
$a molekulární modely $7 D008958
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a protoonkogenní protein MLL $x chemie $x genetika $x metabolismus $7 D051788
650    _2
$a fúzní onkogenní proteiny $x genetika $x metabolismus $7 D015514
650    _2
$a vazba proteinů $7 D011485
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Tesina, Petr $u Institute of Organic Chemistry and Biochemistry of the ASCR, v.v.i., Structural Biology, Prague, Czech Republic. Charles University in Prague, Department of Genetics and Microbiology, Faculty of Science, Prague, Czech Republic.
700    1_
$a Demeulemeester, Jonas $u KU Leuven, Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
700    1_
$a El Ashkar, Sara $u KU Leuven, Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
700    1_
$a Méreau, Hélène $u Department of Biomedicine, University Hospital and Children's Hospital Basel (UKBB) ZLF, Basel, Switzerland.
700    1_
$a Schwaller, Juerg $u Department of Biomedicine, University Hospital and Children's Hospital Basel (UKBB) ZLF, Basel, Switzerland.
700    1_
$a Rezáčová, Pavlína $u Institute of Organic Chemistry and Biochemistry of the ASCR, v.v.i., Structural Biology, Prague, Czech Republic. Institute of Molecular Genetics of the ASCR, v.v.i., Structural Biology, Prague, Czech Republic.
700    1_
$a Veverka, Vaclav $u Institute of Organic Chemistry and Biochemistry of the ASCR, v.v.i., Structural Biology, Prague, Czech Republic. Jan.Derijck@med.kuleuven.be veverka@uochb.cas.cz.
700    1_
$a De Rijck, Jan $u KU Leuven, Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium. Jan.Derijck@med.kuleuven.be veverka@uochb.cas.cz.
773    0_
$w MED00009437 $t Cancer research $x 1538-7445 $g Roč. 74, č. 18 (2014), s. 5139-51
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25082813 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20150424104256 $b ABA008
999    __
$a ok $b bmc $g 1071698 $s 896995
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 74 $c 18 $d 5139-51 $i 1538-7445 $m Cancer research $n Cancer Res $x MED00009437
LZP    __
$a Pubmed-20150420

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace